CHIEF EXECUTIVE OFFICER
Andrew Kocab
Andrew Joseph Kocab signs the October 2026 SEC Form D as Chief Executive Officer. The company’s public profile also identifies him as CEO.
Company public profileFocused on the target.
Grounded in research.
Dvant Pharma is a biotechnology company pursuing new approaches in oncology through EGFR degradation.
From academic science
toward drug development.
University of Michigan Innovation Partnerships lists Dvant in its portfolio of cancer-drug developers, with a launch year of 2021. That is a university-reported launch year, not an asserted exact incorporation date.
Source: University of Michigan · company portfolio
2021
University-reported launch
A February 2021 Regents document describes an EGFR technology license agreement involving Dvant. The historical document supports the research connection; current license scope and commercial rights should be confirmed during diligence.
Read the historical Regents documentScientific purpose.
Company-building focus.
Public company and filing records identify the following leadership and scientific connection.
ACADEMIC FOUNDER
Mukesh Nyati
The company’s public profile identifies Mukesh Nyati as its academic founder. University records document his connection to the underlying EGFR research.
Company public profileDvant Pharma, Inc.
Details below are attributed to the October 13, 2026 SEC filing. A Form D filing is not an endorsement of the company or its research.
- Entity / jurisdiction
- Dvant Pharma, Inc. · Delaware corporation
- Reported principal address
- 3646 Northbrook Drive
Superior Township, MI 48198
United States - Public filing identifier
- CIK 0002158986
- Company contact
- andrew@
dvantpharma.net
SCIENTIFIC & STRATEGIC PARTNERSHIPSMove the science
Connect with Dvant Move the science
forward. Together.
Start a nonconfidential conversation with Dvant Pharma.